| 前收盘价格 | 0.370 |
| 收盘价格 | 0.370 |
| 成交量 | 218,135 |
| 平均成交量 (3个月) | 66,959 |
| 市值 | 45,264,292 |
| 预期市盈率 (P/E Forward) | 116.28 |
| 价格/销量 (P/S) | 2.99 |
| 股市价格/股市净资产 (P/B) | 1.82 |
| 52周波幅 | |
| 利润日期 | 25 Aug 2025 - 29 Aug 2025 |
| 营业毛利率 | -47.87% |
| 营业利益率 (TTM) | -49.16% |
| 稀释每股收益 (EPS TTM) | -0.130 |
| 季度收入增长率 (YOY) | 43.00% |
| 总债务/股东权益 (D/E MRQ) | 19.39% |
| 流动比率 (MRQ) | 3.99 |
| 营业现金流 (OCF TTM) | -12.57 M |
| 杠杆自由现金流 (LFCF TTM) | -10.21 M |
| 资产报酬率 (ROA TTM) | -16.80% |
| 股东权益报酬率 (ROE TTM) | -35.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (AU) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | CYCLOPHARM FPO [CYC] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.13 |
|
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 48.68% |
| 机构持股比例 | 21.62% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合